Page 6 - Demo

EDITOR%u2019S PICKSUCCESSFUL MANAGEMENT OF OVARIAN ADENOCARCINOMA IN AN IVF PREGNANCY %u2014 A RARE CASE REPORTDr. Viveka Jadkar* Senior resident in OBGYN department, Bombay Hospital Institute of Medical Sciences, Mumbai. *Corresponding Author %u2014 Dr. Shivani Agrawal MS OBGYN (Alumni, BHIMS) Dr. Nitin Pai Dhungat Consultant, Bombay HospitalABSTRACT: The occurrence of gynecologic cancer during pregnancy is extremely rare, affecting approximately 4 to 8 pregnancies per 100,000.The frequency of concomitant adnexal tumours in pregnancy is reported to be 0.150- 5.7 %, while ovarian cancer complicates 1 in 15000 - 32000 pregnancies, being the second most common gynaecological cancer during pregnancy following cervical cancer. However, there is increasing incidence of ovarian cancer compared to cervical due to factors such as cervical cancer vaccination and increasing use of ART and increasing maternal age. The diagnosis and management of ovarian cancer during pregnancy remain challenging due to its rarity and the limited data available. Here, we report a case involving a 34-year-old woman diagnosed with a large ovarian adenocarcinoma in the third trimester of pregnancy during routine antenatal scans. The patient was treated with neoadjuvant chemotherapy, followed by an elective cesarean section, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy (HIPEC).Dear readers This case report (pg. no-3) will make an interesting read. We recommend further reading of few facts about monitoring and safety of chemotherapy during pregnancy CA-125 (58.2 U/mL ) could be used as tumor markers in pregnant patients for epithelial ovarian cancer.[1] We are always concerned about safety of chemotherapy during pregnancy. Safety of Mother is most important but literature reports state that it is relatively safer in second and third trimesters, with least risk for fetal complications.A review of 376 fetuses exposed to chemotherapy in utero states only 2.9% malformations.[2] There was 1% neonatal mortality after in utero chemotherapy, which was lower than 17% among the general population globally[3]References1. Xing, N.; Wang, L.; Sui, X.; Zhao, C.; Huang, Y.; Peng, J. The Safety of Chemotherapy for Ovarian Malignancy during Pregnancy. J. Clin. Med. 2022, 11, 7520. https://doi.org/10.3390/jcm112475202. Cardonick, E.; Iacobucci, A. Use of chemotherapy during human pregnancy. Lancet Oncol. 2004, 5, 283%u2013291.]3. World Health Statistics. Monitoring Health for the SDGs, Sustainable Development Goals; World Health Organization: Geneva, Switzerland, 2020.